Clinical Trial Update: Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing cisplatin/etoposide to temozolomide/capecitabine in patients with advanced poorly differentiated gastrointestinal neuroendocrine carci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Neuroendocrine Carcinoma
• Intestinal Neuroendocrine Carcinoma
• Pancreatic Neuroendocrine Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Capecitabine (capecitabine)
• Etoposide (Etoposide)
• Temozolomide (Temozolomide)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-08